Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual MeetingGlobeNewsWire • 02/10/21
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to BuyZacks Investment Research • 01/11/21
Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock OptionsZacks Investment Research • 01/08/21
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing FacilityGlobeNewsWire • 01/07/21
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/23/20
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDGlobeNewsWire • 11/14/20
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/05/20
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 VirtualGlobeNewsWire • 10/20/20
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/10/20
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common StockGlobeNewsWire • 08/18/20
Adverum Biotechnologies Announces $200 Million Public Offering of Common StockGlobeNewsWire • 08/11/20
Adverum Biotechnologies, Inc. (ADVM) CEO Laurent Fischer on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/20
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/29/20
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program StrategyGlobeNewsWire • 07/21/20
Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)GlobeNewsWire • 07/13/20
Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMDGlobeNewsWire • 07/06/20
Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of ManufacturingGlobeNewsWire • 06/25/20